Revelation Biosciences Q2 2026 net loss $3.3M; cash $11.5M, runway into Q1 2027

REVELATION BIOSCIENCES, INC.

2026-Q2 EPS reported -$3.41

Net loss of $3.3M ($0.87 per share) for Q2 2026 vs. $2.4M ($28.04) in Q2 2025.
Cash and cash equivalents $11.5M as of June 30, 2026, up from $10.7M at Dec 31, 2025.
Operating cash burn $2.6M in Q2 2026 vs. $1.9M in Q2 2025.
Phase 2/3 AKI trial startup progressing; independent market assessment shows $94B TAM for Gemini.
Management expects current cash to fund operations through Q1 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.